Pulmonary Tuberculoses Clinical Trial
Official title:
Time-to-Detection in Culture of Mycobacterium Tuberculosis : Performance for Assessing Index Cases Infectivity
| Verified date | October 2022 |
| Source | Centre Hospitalier Universitaire de Nice |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
determination if time-to-detection in cultures of M. tuberculosis samples is more discriminating than acid-fast staining in transmission
| Status | Completed |
| Enrollment | 705 |
| Est. completion date | September 15, 2022 |
| Est. primary completion date | September 15, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 2 Years to 94 Years |
| Eligibility | Inclusion Criteria: - have at least 1 contact case explored for tuberculosis - latent tuberculosis infection Exclusion Criteria: - |
| Country | Name | City | State |
|---|---|---|---|
| France | Nice University Hospital | Nice |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire de Nice |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | tuberculosis transmission | duration of Tuberculosis transmission between an infected person and a contact case | 2 months | |
| Primary | contact case tracking | screening time for contact cases | 2 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04085133 -
Prevalence and Burden of Bronchiectasis in Tuberculous Patients
|
||
| Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
| Completed |
NCT04207112 -
Economic Evaluation of New MDR TB Regimens
|
Phase 2/Phase 3 | |
| Completed |
NCT04044001 -
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03159975 -
Safety and Immunogenicity Study of GX-70 in TB Patient
|
Phase 1 | |
| Completed |
NCT02984579 -
Line Probe Assay Evaluation Study
|
N/A | |
| Recruiting |
NCT04930978 -
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
|
||
| Not yet recruiting |
NCT05477966 -
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress
|
||
| Completed |
NCT05097638 -
Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
|
||
| Active, not recruiting |
NCT05045391 -
Pulmonary Aspergillosis in Tuberculosis Patients
|
||
| Completed |
NCT02754765 -
Evaluating Newly Approved Drugs for Multidrug-resistant TB
|
Phase 3 | |
| Active, not recruiting |
NCT03896685 -
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
|
Phase 3 |